Overview

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

Status:
RECRUITING

Trial end date:
2027-01-15

Target enrollment:

Participant gender:

Summary

This is a study to demonstrate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult patients with active psoriatic arthritis who are naive to biologic disease-modifying antirheumatic drug therapy.

Phase:

PHASE3

Details

Lead Sponsor:

MoonLake Immunotherapeutics AG

Treatments:

sonelokimab